WaveMan · Company
AMS · American Shared Hospital Services
> Search tickers & screens ⌘K
LIVE
← All companies

AMS American Shared Hospital Services (AMS) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0000744825
Quote by TradingView
C-suite buying · 1
Insider net, 180 days
$1.3M
Buys minus sells, Form 4 codes P and S
Insider buyers, 180 days
1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-0.9%
XBRL, annual
Net margin
-5.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.4M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$28.1M
FY Dec 2024$28.3M
FY Dec 2023$21.3M
FY Dec 2022$19.7M
FY Dec 2021$17.6M
Jun 2026$8.4M
Mar 2026$7.1M
Dec 2025$7.7M
Sep 2025$7.2M
Jun 2025$7.1M
Mar 2025$6.1M
Dec 2024$9.1M
Sep 2024$7.0M
At each fiscal year end
Single quarter
Net margin, TTM
-5.8%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-5.5%
FY Dec 2024+7.7%
FY Dec 2023+2.9%
FY Dec 2022+6.7%
FY Dec 2021+1.1%
Jun 2026-6.1%
Mar 2026-8.6%
Dec 2025-8.2%
Sep 2025-0.2%
Jun 2025-4.0%
Mar 2025-10.2%
Dec 2024-14.6%
Sep 2024-3.0%
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025-$4.5M
FY Dec 2024-$7.8M
FY Dec 2023-$555.0K
FY Dec 2022$6.8M
FY Dec 2021$4.6M
Jun 2026$2.2M
Mar 2026$2.1M
Dec 2025$1.3M
Sep 2025-$2.0M
Jun 2025-$2.3M
Mar 2025-$1.5M
Dec 2024-$4.4M
Sep 2024-$407.0K
At each fiscal year end
Single quarter
Debt to equity
0.70x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
History
FY Dec 20250.72x
FY Dec 20240.80x
FY Dec 20230.58x
FY Dec 20220.62x
FY Dec 20210.77x
Jun 20260.70x
Mar 20260.72x
Dec 20250.72x
Sep 20250.74x
Jun 20250.78x
Mar 20250.81x
Dec 20240.80x
Sep 20240.54x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.33x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
History
FY Dec 20250.18x
FY Dec 20240.01x
FY Dec 20230.44x
FY Dec 20220.54x
FY Dec 20210.41x
Jun 20260.33x
Mar 20260.16x
Dec 20250.18x
Sep 20250.22x
Jun 20250.15x
Mar 20250.23x
Dec 20240.01x
Sep 2024-0.22x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-7.5%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-6.3%
FY Dec 2024+9.1%
FY Dec 2023+2.8%
FY Dec 2022+6.4%
FY Dec 2021+1.0%
Jun 2026-7.5%
Mar 2026-6.4%
Dec 2025-6.3%
Sep 2025-8.8%
Jun 2025-9.6%
Mar 2025+6.1%
Dec 2024+9.1%
Sep 2024+16.2%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.1%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-2.7%
FY Dec 2024+4.0%
FY Dec 2023+1.3%
FY Dec 2022+3.0%
FY Dec 2021+0.4%
Jun 2026-3.1%
Mar 2026-2.6%
Dec 2025-2.7%
Sep 2025-3.7%
Jun 2025-3.9%
Mar 2025+2.5%
Dec 2024+4.0%
Sep 2024+7.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022+6.3%
FY Dec 2021+3.3%
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024-2.3%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-9.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-8.8%
FY Dec 2024-6.4%
FY Dec 2023+0.7%
FY Dec 2022+6.2%
FY Dec 2021+3.8%
Jun 2026-9.8%
Mar 2026-7.9%
Dec 2025-8.8%
Sep 2025-10.1%
Jun 2025-10.1%
Mar 2025-8.9%
Dec 2024-6.4%
Sep 2024-1.4%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 20249.67x
FY Dec 202323.80x
FY Dec 202213.95x
FY Dec 202179.00x
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 202513.24x
Dec 20249.67x
Sep 20245.00x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$18.5M
market value at close 2026-10-09 on 2026-08-11 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
History
FY Dec 2025$27.6M
FY Dec 2024$29.6M
FY Dec 2023$14.4M
FY Dec 2022$19.2M
FY Dec 2021$21.2M
Jun 2026$20.2M
Mar 2026$21.4M
Dec 2025$27.6M
Sep 2025$31.3M
Jun 2025$23.6M
Mar 2025$26.6M
Dec 2024$29.6M
Sep 2024$19.9M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+40.3%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025-32.9%
FY Dec 2024-37.9%
FY Dec 2023-3.7%
FY Dec 2022+38.0%
FY Dec 2021+33.0%
Jun 2026+33.8%
Mar 2026-9.6%
Dec 2025-32.9%
Sep 2025-56.0%
Jun 2025-55.2%
Mar 2025-34.8%
Dec 2024-37.9%
Sep 2024-33.7%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 20240.04x
FY Dec 2023n/a
FY Dec 20220.02x
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 20250.10x
Dec 20240.04x
Sep 20240.01x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

AMS Stock Sonar score 5/7 axes

Find similar shapesCompare

AMS ranks highest on insider conviction (80th percentile) and financial health (53rd), and lowest on growth (23rd), among Healthcare Services peers.

ProfitHealthGrowthInsidersRisk
Profitability
41
Inputs
  • Return on equity-7.5% · 43 pct, sector of 70
  • Return on assets-3.1% · 49 pct, sector of 88
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-9.8% · 31 pct, sector of 68
Financial health
53
Inputs
  • Debt to equity0.70x · 38 pct, sector of 61
  • Cash flow to debt0.33x · 68 pct, sector of 66
Growth
23
Inputs
  • Revenue growth, YoY-0.9% · 23 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
80
Inputs
  • Net open-market buying, 180d$1.3M · 94 pct, sector of 67
  • Insider buyers, 180d1 · 65 pct, sector of 67
Risk and compliance
45
Inputs
  • Short interest, % of float+0.2% · 85 pct, sector of 95
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+27.1% · 4 pct, sector of 71
2 not measured: Institutional and government, US patents
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

What the filings say about AMS

In the 180 days to 2026-10-12, American Shared Hospital Services insiders were net buyers of AMS, a net $1.3M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $1.3M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.

AMS filings FAQ

Are American Shared Hospital Services insiders buying or selling AMS?

In the 180 days to 2026-10-12, American Shared Hospital Services insiders were net buyers, a net $1.3M across purchases and sales reported on Form 4, by 1 buyer.

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.3M over 180 days
+$1.3M of it by a 10%+ holder
more than 94% of Healthcare Services
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-0.9% year over year
below 77% of Healthcare Services
Margin
-5.5% net margin
below 59% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
below 80% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AMS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-47.8%12M
-49%-33%-16%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-06-22 · Stachowiak Raymond C bought $1.3M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.3M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

American Shared Hospital Services insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AMERICAN SHARED HOSPITAL SERVICES insiders bought a net $1.3M of stock across 1 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Stachowiak Raymond C
Executive Chairman
BUY
2026-06-22
586,468
$1.3M
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 586,468 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Executive Chairman Stachowiak Raymond C bought about $1.3M of AMS on the open market on Jun 22, 2026, the largest insider purchase at the company on our record.
1 transaction on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns AMS: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in AMS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AMS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Raymond C. Stachowiak
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$526.4K
$523.2K
$385.9K
-29%
n/a
2024
$603.3K
$666.6K
$464.6K
+32%
n/a
2023
$626.6K
$588.5K
$395.0K
-19%
n/a
2022
$560.0K
$574.4K
$323.6K
+22%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$28.1M$28.3M$21.3M$19.7M
Gross profit$5.1M$9.2M$9.3M$8.4M
Operating income$-3.6M$-2.8M$270.0K$2.4M
Net income$-1.6M$2.2M$610.0K$1.3M
EPS (diluted)-0.230.330.100.21
Operating cash flow$3.1M$167.0K$5.7M$7.2M
Cash$3.5M$11.0M$13.7M$12.3M
Long-term debt$0$17.3M$11.0M$12.2M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies